DeutschNewstral
Article
Forbes on 2017-11-09 16:03
New Drug Eases Postpartum Depression In Victory For Tiny Sage Therapeutics
Related news
Sage Therapeutics surges on postpartum depression drug studyseattletimes.com
Sage Therapeutics to seek approval of postpartum depression drug after trial winbizjournals.com- MSage Therapeutics shares surge 45% on positive trail of postpartum depression drugmarketwatch.com
- BSage Stock Rises on Postpartum Depression Drug Data3 min readbarrons.com
FDA approves first postpartum depression drugCNN- Pill for postpartum depression by Cambridge's Sage succeeds in late-stage trialbizjournals.com
- Sage Therapeutics gains $220M in value as depression drug clears trial hurdlebizjournals.com
FDA approves first drug specifically for postpartum depressionWashington Post- MSage Therapeutics stock bounces 49% after positive results for depression treatmentmarketwatch.com
- BSage Therapeutics Is Cratering Because Its Depression Treatment Failed In A Key Trialbarrons.com
- Promising drug by Sage Therapeutics helps treat post-partum depression in mid-stage trialbizjournals.com
Postpartum depression drug OK’dnwaonline.com
US approves first pill to treat postpartum depressionAl Jazeera- MSage Therapeutics stock surges 50% on positive trial results in postpartum depressionmarketwatch.com
- Sage Therapeutics asks FDA to approve lead drug for postpartum depressionbizjournals.com
- Does Sage Therapeutics' Failure Predict Its Future Results?Forbes
- NFDA approves 1st drug for treating postpartum depressionnypost.com
- With new promise in post-partum depression, Sage is no longer all about epilepsybizjournals.com